Deleted Tweets From Scott Gottlieb, R-D.C.

.@US_FDA continues to take actions to prevent future foodborne outbreaks through surveillance sampling. Here, an #FDA Consumer Safety Officer in Nogales, AZ, collects a sample of fresh produce (sweet peppers) to be analyzed by an FDA laboratory for microbiological contamination. https://t.co/KTALQ1dP9N

RT @SGottliebFDA: My statement on the unprecedented work done by #FDA to proactively design, test and validate the key labeling requirements necessary to approve an OTC version of naloxone and make it available to patients. https://t.co/YOG2TXo96n https://t.co/10aPCTsLWN

RT @califf001: Important work by FDA to deal with overdoses--this will make a difference. The followup after the overdose will be critical. @DukeForge https://t.co/c3zSR0m8GK

RT @angelicalavito: FDA clears way to lower cost of opioid overdose treatment naloxone https://t.co/cZD861hVCr

This week #FDA investigators at the International Mail Facility in Puerto Rico prepared intercepted counterfeit and/or misbranded drugs totaling 800 pounds of illegal product for transport to the mainland for destruction. #OnTheJob #MissionCritical https://t.co/DLdWD7RvVZ

Drug user fees must be spent on review related work by law. As review workload declines, because we’re not receiving new applications, we’ll have to furlough more people who are in user-fee slots. This is among the hardest, most painful decision we’ll make https://t.co/EMl0KgKQW8

Certain discretionary activities, especially those that are supported by a mix of user fees and budget authority (like developing certain guidance documents) also can’t go on as the lapse in funding continues. This is also reducing user-fee-related workloads.

#FDA is taking unprecedented new steps to advance development of an over-the-counter version of Naloxone to help reduce opioid overdose deaths https://t.co/GRX1s8KS2Q

We’re looking for new ways we can help our employees on furlough. We miss our valued teammates very much and are planning ways to reconnect and support them. We’re one #FDA.

#FDA is committed to reversing the youth trends. In November, we announced our development of a revised policy framework focused on ways to ensure that flavored e-cigarette products are sold in ways that make them less accessible and appealing to minors: https://t.co/vXgccUt9xw

Animal care is ongoing at #FDA’s Center for Veterinary Medicine. Our staff is making sure our young cows have fresh water and food; and our research biologists are caring for our salmon, trout and tilapia in our aquaculture facility, among many others. We love our animals! https://t.co/jwOILlw9gv

We must not only seek to develop evidence-based programs to prevent youth and young adults from using tobacco in any form; we must also explore evidence-based approaches to address existing youth tobacco use

THREAD: Today #FDA is holding a public hearing to discuss #FDA’s continued efforts to address growing epidemic of youth e-cigarette use, including potential new therapies to support cessation. Read my remarks presented this morning: https://t.co/vXgccUt9xw

We’re hopeful this hearing will serve as a valuable conduit to support the elimination of youth e-cigarette use. No child should be using any tobacco/nicotine-containing product. We need to do everything possible to reverse this trend and help kids who may already be addicted.

RT @califf001: hard trade-offs with vaping for helping stop tobacco use vs creating a new generation of people addicted to nicotine. Need research to provide evidence--academic centers need to step up with this. @DukeForge https://t.co/OedtfwLhEl

I still believe e-cigarettes present an opportunity for adult smokers to transition off cigarettes and onto nicotine delivery products that may not have the same level of risks. However, if the youth use continues to rise, the entire category will face an existential threat

Today, #FDA approved Ontruzant, the 3rd #biosimilar to Herceptin. All FDA approved #biosimilar products meet the FDA’s robust scientific standards. https://t.co/EMvwEr1EZn

How does a new commissioner go about becoming Chairman? https://t.co/BDfuHlMoaT QT @AjitPaiFCC: )

With today’s approval, #FDA has approved 17 #biosimilars to date. More approved biosimilars help to promote competition that can lower health care costs and increase patient access. Our list of approved biosimilars: https://t.co/iudlkellOH

To address patient hardships created by the Byzantine if not predatory pricing practices the author describes; #FDA outlined a framework to open insulin products up to Biosimilar competition, making low cost copies easier to develop https://t.co/PlrVRMX6TA https://t.co/BQiIi6VF7M

.@US_FDA continues to take actions to prevent future foodborne outbreaks through surveillance sampling. Here, an #FDA Consumer Safety Officer in Nogales, AZ, collects a sample of fresh produce (sweet peppers) to be analyzed by an FDA laboratory for microbiological contamination. https://t.co/KTALQ1dP9N

RT @SGottliebFDA: My statement on the unprecedented work done by #FDA to proactively design, test and validate the key labeling requirements necessary to approve an OTC version of naloxone and make it available to patients. https://t.co/YOG2TXo96n https://t.co/10aPCTsLWN

RT @califf001: Important work by FDA to deal with overdoses--this will make a difference. The followup after the overdose will be critical. @DukeForge https://t.co/c3zSR0m8GK

RT @angelicalavito: FDA clears way to lower cost of opioid overdose treatment naloxone https://t.co/cZD861hVCr

This week #FDA investigators at the International Mail Facility in Puerto Rico prepared intercepted counterfeit and/or misbranded drugs totaling 800 pounds of illegal product for transport to the mainland for destruction. #OnTheJob #MissionCritical https://t.co/DLdWD7RvVZ

Drug user fees must be spent on review related work by law. As review workload declines, because we’re not receiving new applications, we’ll have to furlough more people who are in user-fee slots. This is among the hardest, most painful decision we’ll make https://t.co/EMl0KgKQW8

Certain discretionary activities, especially those that are supported by a mix of user fees and budget authority (like developing certain guidance documents) also can’t go on as the lapse in funding continues. This is also reducing user-fee-related workloads.

#FDA is taking unprecedented new steps to advance development of an over-the-counter version of Naloxone to help reduce opioid overdose deaths https://t.co/GRX1s8KS2Q

We’re looking for new ways we can help our employees on furlough. We miss our valued teammates very much and are planning ways to reconnect and support them. We’re one #FDA.

#FDA is committed to reversing the youth trends. In November, we announced our development of a revised policy framework focused on ways to ensure that flavored e-cigarette products are sold in ways that make them less accessible and appealing to minors: https://t.co/vXgccUt9xw

Animal care is ongoing at #FDA’s Center for Veterinary Medicine. Our staff is making sure our young cows have fresh water and food; and our research biologists are caring for our salmon, trout and tilapia in our aquaculture facility, among many others. We love our animals! https://t.co/jwOILlw9gv

We must not only seek to develop evidence-based programs to prevent youth and young adults from using tobacco in any form; we must also explore evidence-based approaches to address existing youth tobacco use

THREAD: Today #FDA is holding a public hearing to discuss #FDA’s continued efforts to address growing epidemic of youth e-cigarette use, including potential new therapies to support cessation. Read my remarks presented this morning: https://t.co/vXgccUt9xw

We’re hopeful this hearing will serve as a valuable conduit to support the elimination of youth e-cigarette use. No child should be using any tobacco/nicotine-containing product. We need to do everything possible to reverse this trend and help kids who may already be addicted.

RT @califf001: hard trade-offs with vaping for helping stop tobacco use vs creating a new generation of people addicted to nicotine. Need research to provide evidence--academic centers need to step up with this. @DukeForge https://t.co/OedtfwLhEl

I still believe e-cigarettes present an opportunity for adult smokers to transition off cigarettes and onto nicotine delivery products that may not have the same level of risks. However, if the youth use continues to rise, the entire category will face an existential threat

Today, #FDA approved Ontruzant, the 3rd #biosimilar to Herceptin. All FDA approved #biosimilar products meet the FDA’s robust scientific standards. https://t.co/EMvwEr1EZn

How does a new commissioner go about becoming Chairman? https://t.co/BDfuHlMoaT QT @AjitPaiFCC: )

With today’s approval, #FDA has approved 17 #biosimilars to date. More approved biosimilars help to promote competition that can lower health care costs and increase patient access. Our list of approved biosimilars: https://t.co/iudlkellOH

To address patient hardships created by the Byzantine if not predatory pricing practices the author describes; #FDA outlined a framework to open insulin products up to Biosimilar competition, making low cost copies easier to develop https://t.co/PlrVRMX6TA https://t.co/BQiIi6VF7M